Report Says MSD Is in Talks to Buy Revolution Meds

Why It Matters

Securing Revolution’s RAS inhibitors would give MSD a next‑generation oncology platform as Keytruda faces generic competition, while the deal could spark a bidding war that reshapes the pharma M&A landscape.

Key Takeaways

• MSD may acquire Revolution for up to $32 billion
• Revolution's lead drug daraxonrasib targets pancreatic and lung cancers
• Potential bidding war could involve AbbVie, Amgen, Eli Lilly
• Deal would offset MSD's upcoming Keytruda patent expiry
• Pan‑RAS inhibitor market crowded; Revolution leads with pivotal trials

Pulse Analysis

Merck & Co (MSD) has been on an acquisition binge, spending roughly $30 billion on four bolt‑on deals since 2024. The latest rumour of a $28‑$32 billion bid for Revolution Medicines follows Amgen’s $840 million purchase of Dark Blue Therapeutics and Eli Lilly’s $1.2 billion takeover of Ventyx Bio, underscoring a wave of consolidation in oncology. With Keytruda’s patent cliff looming in 2028, MSD is seeking high‑value assets that can sustain its revenue base and keep it competitive against rivals such as Pfizer and Novartis.

Revolution’s lead candidate, daraxonrasib, is a pan‑RAS inhibitor that could address two of the toughest solid‑tumour indications—pancreatic ductal adenocarcinoma and non‑small cell lung cancer—where treatment options remain limited. The drug is already in registration‑stage trials, giving it a clear advantage over the dozen other RAS programs still in early development. Complementary assets like the KRAS G12C inhibitor elironrasib and the G12D inhibitor zoldonrasib broaden the portfolio, positioning the company as a one‑stop shop for next‑generation RAS‑targeted therapies.

If the deal closes, it would likely trigger a bidding war, with AbbVie, Amgen and possibly other majors weighing offers, which could drive the final price higher and set a new benchmark for oncology M&A. For investors, the transaction promises a pipeline that may offset the revenue dip from Keytruda’s generic erosion, while also delivering growth in high‑margin cancer drugs. Regulators will scrutinise the scale of the merger, but the strategic fit and market momentum suggest the acquisition could reshape the competitive dynamics of the RAS inhibitor space.